Radical resection in entero-pancreatic neuroendocrine tumors: recurrence-free survival rate and definition of a risk score for recurrence
Bartsch, D. K.
McNamara, Mairead G
de Herder, W.
Valle, Juan W
Gress, T. M.
Fave, G. D.
de Pretis, G.
Pavel, M. E.
AffiliationDepartment of Medicine 1, Division of Endocrinology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
MetadataShow full item record
AbstractBackground: Surgery with radical intent is the only potentially curative option for entero-pancreatic neuroendocrine tumors (EP-NETs) but many patients develop recurrence even after many years. The subset of patients at high risk of disease recurrence has not been clearly defined to date. Objective: The aim of this retrospective study was to define, in a series of completely resected EP-NETs, the recurrence-free survival (RFS) rate and a risk score for disease recurrence. Patients and methods: This was a multicenter retrospective analysis of sporadic pancreatic NETs (PanNETs) or small intestine NETs (SiNETs) [G1/G2] that underwent R0/R1 surgery (years 2000-2016) with at least a 24-month follow-up. Survival analysis was performed using the Kaplan-Meier method and risk factor analysis was performed using the Cox regression model. Results: Overall, 441 patients (224 PanNETs and 217 SiNETs) were included, with a median Ki67 of 2% in tumor tissue and 8.2% stage IV disease. Median RFS was 101 months (5-year rate 67.9%). The derived prognostic score defined by multivariable analysis included prognostic parameters, such as TNM stage, lymph node ratio, margin status, and grading. The score distinguished three risk categories with a significantly different RFS (p < 0.01). Conclusions: Approximately 30% of patients with EP-NETs recurred within 5 years after radical surgery. Risk factors for recurrence were disease stage, lymph node ratio, margin status, and grading. The definition of risk categories may help in selecting patients who might benefit from adjuvant treatments and more intensive follow-up programs.
CitationMerola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, et al. Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022.
JournalAnnals of Surgical Oncology
- Clinicopathological characteristics and risk factors for recurrence of well-differentiated pancreatic neuroendocrine tumors after radical surgery: a case-control study.
- Authors: Zhang P, Li YL, Qiu XD, Luo J, Shi YF, Sun YL, Su F, Qi ZR, Tan HY
- Issue date: 2019 Apr 11
- A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.
- Authors: Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idrees K, Cho CS, Weber SM, Fields RC, Staley CA 3rd, Falconi M, Maithel SK
- Issue date: 2019 Sep
- Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
- Authors: Tong Z, Liu L, Zheng Y, Jiang W, Zhao P, Fang W, Wang W
- Issue date: 2017 May 30
- Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.
- Authors: Genç CG, Falconi M, Partelli S, Muffatti F, van Eeden S, Doglioni C, Klümpen HJ, van Eijck CHJ, Nieveen van Dijkum EJM
- Issue date: 2018 Aug
- Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
- Authors: Merola E, Rinke A, Partelli S, Gress TM, Andreasi V, Kollár A, Perren A, Christ E, Panzuto F, Pascher A, Jann H, Arsenic R, Cremer B, Kaemmerer D, Kump P, Lipp RW, Agaimy A, Wiedenmann B, Falconi M, Pavel ME
- Issue date: 2020 May